Skip to main content

Elana Lerner Brockmann

Associate

[email protected]

+1.617.239.8401

Share:

Elana focuses her practice on corporate transactions, including IPOs and mergers and acquisitions, and a broad range of general corporate matters.

Prior to completing her law degree, Elana worked as a Summer Associate at Mintz. In that role, she assisted with a broad range of corporate transactions for life sciences companies. She also served as a legal intern in the general counsel’s office of a nonprofit academic medical center in Boston. Her work in that position included conducting legal research related to health care, hospital operations, and health insurance and writing memoranda on telehealth policies.

In law school, Elana was a staff editor and a staff writer for the Boston College Intellectual Property & Technology Forum. She also served as a staff attorney for BC Law’s Community Enterprise Clinic and Defenders Lifer Parole Clinic and was recognized for Pro Bono Excellence as a Public Interest Designation Program Fellow for completing more than 100 hours of pro bono service before graduation.

Elana is a nationally certified occupational therapist. She wrote a doctoral thesis titled “Optimizing the Inclusion of Occupational and Physical Therapy Services in the Current Health Care Delivery Model at Boston Medical Center (BMC).”

viewpoints

Florida has joined the growing list of states enacting comprehensive privacy laws. Governor Ron DeSantis (R) signed the Florida Digital Bill of Rights (“FDBR”) into law on June 6th.

Read more
Read less

News & Press

Press Release Thumbnail Mintz

Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Press Release Thumbnail Mintz

Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.

News Thumbnail Mintz

Law360 published an article written by Privacy & Cybersecurity Chair Cynthia Larose, and Associates Michael Katz and Elana Lerner Brockman, which analyzes the Florida Digital Bill of Rights.

Read less

Publications

Author, Data Privacy Concerns Regarding COVID-19 Contact Tracing Apps and Implications for the Field of Cybersecurity, Boston College Intellectual Property & Technology Forum (September 2021)

Read less